BIM
MRTX

BlackRock Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BlackRock Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$207K Hold
43,605
– – ﹤0.01% 3225
2016
Q3 		$288K Sell
43,605
-103
-0.2% -$548 ﹤0.01% 3190
2016
Q2 		$239K Buy
43,708
+3,103
+8% +$49.5K ﹤0.01% 3264
2016
Q1 		$869K Buy
40,605
+863
+2% +$19.3K ﹤0.01% 2578
2015
Q4 		$1.26M Buy
39,742
+278
+0.7% +$9.82K ﹤0.01% 2434
2015
Q3 		$1.36M Buy
39,464
+4,473
+13% +$135K ﹤0.01% 2367
2015
Q2 		$1.1M Buy
34,991
+10,266
+42% +$303K ﹤0.01% 2696
2015
Q1 		$725K Buy
24,725
+4,216
+21% +$98.9K ﹤0.01% 2751
2014
Q4 		$380K Buy
20,509
+262
+1% +$4.42K ﹤0.01% 3117
2014
Q3 		$355K Buy
20,247
+332
+2% +$6.2K ﹤0.01% 3127
2014
Q2 		$398K Buy
+19,915
New +$385K ﹤0.01% 3132

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BlackRock Investment Management's MRTX Position: Q4 2016 in Review

BlackRock Investment Management held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q4 2016 at 43,605 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #3225.

BlackRock Investment Management first reported a position in MRTX in Q2 2014 and has held it in 11 quarters since. The position peaked at $1.36M in Q3 2015. 62 funds tracked by Wall St. Rank hold MRTX as of Q4 2016.

  • BlackRock Investment Management held 43,605 shares of Mirati Therapeutics, Inc. Common Stock worth $207K as of Q4 2016.
  • BlackRock Investment Management left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q4 2016.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3225 holding.
  • BlackRock Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 11 quarters since.
  • BlackRock Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $1.36M in Q3 2015.
  • 62 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.